H
IV and HIV-infected ceils are not lysed by human complement; even in the presence of HIV-specific antibodies, lysis is only partial (1--4) . This intrinsic resistance is not due to a failure of HIV surface glycoproteins to interact with complement proteins, since HIV, HIVinfected ceils, and purified HIV envelope proteins bind complement proteins with activating functions like Clq or Mannan binding protein (1, 5, 6) and trigger complement fixation. Resistance of HIV to complement could in part be explained by the presence of decay accelerating factor (DAF, CD55) and CD59 on the surface of HIV; covering DAF or CD59 with specific antibodies eliminated their protective effect and resulted in partial lysis of lab strains by normal human serum (NHS) (7, 8) . Recently, interaction of complement factor H (CFH), a negative regulator of complement activation, with both envelope glycoproteins of HIV-1, gp120 and gp41, was independently described by . CFH down-regulates the amplification loop of complement activation and acts as cofactor for inactivation of C3b to iC3b (13, 14) . In contrast to C3b, iC3b does not provide further activation of the complement system, and as a consequence, membrane attack complex (MAC) formation does not occur (15) . Here we show that resistance to human complement can be completely overcome if DAF and CFH (300-500 Ixg/ml in NHS) are set out of function.
Materials and Methods

CFH-depleted Human Serum Was Represented by Genetically CFH-deficient Serum or Prepared fiom NHS.
Lyophilized and titrated human plasma (S-1767; Sigma Chemical Co., St. Louis, MO) was dissolved in ice-cold ultrapure water and depleted of CFH by incubation with CNBr-activated Sepharose (Pharmacia, Uppsala, Sweden) coupled with the mAb 5H5, specific for human CFH (9) . Uncoupled Sepharose beads were used as a control to show that depletion was due to the antibody and not to unspecific adsorption to Sepharose. The amount of Sepharose-bound mAb was used in a sixfold excess as compared with the calculated amount of CFH present in the plasma sample. Incubation was performed at 4~ for 2 h. CFH concentration was checked after sample collection in ELISA and SDS-PAGE, followed by Western blot. All Sepharose supernatants were filter sterilized before use in cell assays.
Purification of Antibodies from Sera of Patients with AIDS and NHS.
IgG from sera of AIDS patients and from NHS were purified from the pass-through of a DEAE Affi-Gel Blue column (BioKad, Richmond, CA) and vacuum ulrafiltration on membranes (Micro Prodicon; Spectrum, Houston, TX) with a 100-kD cut-off, to eliminate transferrin. The AIDS sera used as a source of human AIDS Ig were chosen on the basis of their reactivity in ELISA assays against gp120 and gp41 (American Biotechnologies, Cambridge, MA). Normal sera were controlled for the absence of anti-env antibodies with the same method. Complement-mediated Lysis Of HIV. NHS or serum from a patient with genetic CFH deficiency (CFH a~f) (16) (both end dilutions 1:10) was incubated with purified antibodies isolated from HIV + (Ig anti-HIV) on ice. In some cases, polyclonal antibodies against DAF (anti-DAF) were added (end dilution 1:100). The solutions were transferred to an ELISA plate, which was precoated with antibodies against p24. Constant amounts of primary isolates (92P, W021, 92TH024, IBK-0295) and the lab strain HIV-IIIB were added, and the mixture was incubated for 1 h at 37~ to allow complement-mediated lysis of viral particles and release of p24 in the absence of detergent. Free p24 in the supernatant, an indicator for lysis and neutralization of HIV (8, 17) , bound to the antibody on the ELISA plate. After four washing cycles with PBS without detergent, a second antibody against p24 was added, followed by two further washing steps with PBS and two with PBS, containing 0.1% Tween 20. The ELISA was developed with biotinstreptavidin, and the optical density of the samples (ODsampl~) was measured. NP-40 was used to determine 100% lysis (ODNP40) and the background (ODback) by incubation of HIV with NHS without lg anti-HlV. The percentage of lysis was calculated by the following formula: (ODsample-ODback/ODNP40-ODback) X 100. The experiments were performed in duplicate.
Assay of Complement-dependent Cytotoxicity (CDC)
.
Results and Discussion
To test the hypothesis that direct binding of CFH to the envelope of HIV-1 might protect the virus from destruction by human serum, 8E5 cells, chronically infected with HIV (18) , and noninfected CEM cells were pretreated with Ig obtained from HIV + or healthy individuals and exposed to NHS cFH-. As shown in Fig. 1 , only HIV-infected cells were susceptible to CDC. Furthermore, CDC was strictly dependent on the use of NHSCFH-; application of NHS instead of NHS cFH-had no destructive effect. To prove for- mally the protective role of CFH, NHS cFH-was reconstituted with increasing amounts of CFH. 50% protection of HIV-infected cells could be obtained by the addition of 0-~8 Ixg CFH/ml (Fig. 2 ), corresponding to a reconstitution of ~5% of the normal CFH concentration in plasma.
In the next set of experiments, free viral particles from different primary isolates, 92RW021, 92TH024, IBK-0295, and lab strain HIV-IIIB, were incubated with NHS or NHS cFH , each in combination with different antibodies. In accordance with Spear et al. (4) , in the presence of HIV-specific antibodies and NHS complement-dependent virolysis, up to 30% lysis in the case of HIV-IIIB was obtained. Primary isolates were more resistant to lysis, that is, only 12% lysis was obtained with IBK-0295, a virus isolated from an Innsbruck patient and passaged only once for these experiments. Therefore, 88% of this isolate was unaffected by human complement (Fig. 3) . Lysis could be considerably increased by the presence of an antibody against DAF, eliminating the DAF-mediated anticomplement effect. Incubation of various HIV strains with Ig anti-HIV lates (the lab strain HIV-IIIB and three primary isolates) were incubated with NHS or serum from a patient with total CFH def in the presence of purified lgG from sera of HIV + individuals (Ig anti-HIV). In some assays, anti-DAF antibodies were added as indicated. The percentage of complement-mediated lysis was monitored by measuring free p24 in the supernatant as described in Materials and Methods.
and serum derived from a patient with total C F H d~f resulted in release of 85% of total p24, indicating a very efficient inactivation of HIV. These findings clearly demonstrate that C F H is the main contributor to resistance of HIV against lysis by human complement. Interestingly, a comparable defense strategy was shown for streptococci, which bind C F H on their surface protein M (19) . C o mbining C F H def and anti-DAF in the presence of Ig anti-HIV, nearly all free HIV particles were destroyed through the lytic action of human complement (Fig. 3) . To prove directly whether binding o f C F H to gp41 was critical for C F H -m e d i a t e d protection, the different HIV strains were tested in the presence of mAb 2F5. This antibody covers the E L D K W A S motif in gp41 (aa 665-671 in HIV-IIIB) and is known to neutralize HIV in vitro (17) ; in addition, this site in gp41 was described as a binding region for factor H (8-11). As shown in Fig. 3 , incubation of HIV with 2F5 and addition of N H S in combination with Ig anti-HIV lead to the destruction of ~6 0 % of available HIV. Obviously, the CFH-mediated protection of HIV from complement-dependent lysis was abrogated because of interference by mAb 2F5 with C F H binding to the E L D K W A S motif of the viral envelope protein.
These results suggest that DAF as part of the viral m e mbrane find exogenous C F H secondarily attached to the HIV envelope proteins together are sufficient to explain the efficient, intrinsic resistance of HIV to human complement. Overcoming these two barriers should be appropriate goals for new vaccine strategies. By activating complement, HIV coats itself with C3, thus enhancing its infectivity and providing, for example, for follicular localization (20) (21) (22) (23) (24) while avoiding complement-mediated destruction via complement control proteins DAF and CFH. This mechanism might represent a general strategy also used by other complementresistant human retroviruses.
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